Jenapharm

Jenapharm GmbH & Co. KG
legal form	GmbH & Co. KG
founding	1950 (as VEB Jenapharm)
Seat	Jena , Germany
management	Olaf Gerber
Number of employees	160 (2014)
sales	170 million euros (2014)
Branch	pharmacy
Website	www.jenapharm.de
	Status: February 2015

The listed Zeiss Building 23 in Jena is the location of the pharmaceutical company.

The Jenapharm GmbH & Co. KG is a pharmaceutical company based in Thuringia Jena .

The company, which was founded in 1950, has been part of Bayer AG since 2006 . It sells preparations for contraception , menopausal symptoms , gynecological diseases , dermatology and andrology . The company is the German market leader for oral contraceptives with a market share of 32.4 percent.

history

The microbiologist Hans Knöll introduced the first large-scale penicillin production on the European mainland in Jena in 1942 . The state-owned company Jenapharm was established in 1950 from the bacteriological laboratory of the Schott glassworks that he had previously founded .

The focus of research in 1952 was on steroid hormones . In the early 1960s, a totally synthetic process ( Torgov synthesis ) was developed for the production of sex hormones. The birth control pill Ovosiston was approved in the GDR in 1965 . The company thus initially became the leading manufacturer of these contraceptives and was able to export to several countries in Central and Eastern Europe in a short time.

The preparation Klimonorm with the ingredient levonorgestrel for the treatment of menopause was introduced in 1990. The following year, the Treuhand sold Jenapharm GmbH to the Stuttgart- based pharmaceutical wholesaler Gehe AG . In the following four years, the existing systems were modernized and a production facility was opened in neighboring Weimar .

In 1995, the micro-pill Valette with the active ingredient Dienogest for contraception was brought onto the market. Shortly thereafter, Berliner Schering AG took over the majority of Jenapharm's shares. The birth control pill petibelle with the progestin drospirenone was introduced in 2000. In 2001 Lafamme came onto the market for the treatment of menopausal symptoms and Schering AG took over the remaining shares in the company.

Jenapharm developer and provider of intrauterine Mirena , Jaydess and Kyleena .

The andrology business area was founded in 2002 and the testosterone preparation Testogel was introduced one year later. After the therapeutic division was sold to Dermapharm AG in 2004 , the focus was on the core business of gynecology . In 2006 the product aida was launched.

In July 2018, long-time managing director Michael Raps gave up his office. Olaf Gerber followed him.

Doping in the GDR with a Jenapharm product

Oral Turinabol

The state-prescribed doping in GDR competitive sport was carried out for years with anabolic steroids , including the Oral-Turinabol® developed by Jenapharm , which many competitive athletes took, sometimes without wanting to. Lawsuits and court hearings followed in 2005. An agreement was reached in December 2006. The athletes received compensation, in which Jenapharm participated.